153 related articles for article (PubMed ID: 8980999)
1. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
2. T3-release from autonomously functioning thyroid nodules in vitro.
Poertl S; Kirner J; Saller B; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1998; 106(6):489-93. PubMed ID: 10079030
[TBL] [Abstract][Full Text] [Related]
3. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
4. Thyrotropin receptor: a role for thyroid tumourigenesis?
Russo D; Arturi F; Chiefari E; Filetti S
Forum (Genova); 1999; 9(2):166-75. PubMed ID: 10385711
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
6. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of iodine deficiency and secondary and TSH-independent molecular mechanisms.
Derwahl M; Manole D; Sobke A; Broecker M
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S6-9. PubMed ID: 9867188
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
Derwahl M; Hamacher C; Russo D; Broecker M; Manole D; Schatz H; Kopp P; Filetti S
J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855
[TBL] [Abstract][Full Text] [Related]
10. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
Derwahl M
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
12. Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas.
Derwahl M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():32-5. PubMed ID: 8980997
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
15. Activation of the cAMP cascade in thyroid autonomy.
Paschke R
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S4-5. PubMed ID: 9867187
[No Abstract] [Full Text] [Related]
16. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
17. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor].
Kosugi S
Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916
[TBL] [Abstract][Full Text] [Related]
18. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
Derwahl M
J Clin Endocrinol Metab; 1996 Aug; 81(8):2783-5. PubMed ID: 8768829
[TBL] [Abstract][Full Text] [Related]
19. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M
J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells.
Fournes B; Monier R; Michiels F; Milgrom E; Misrahi M; Feunteun J
Oncogene; 1998 Feb; 16(8):985-90. PubMed ID: 9519872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
